U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H9NO2
Molecular Weight 139.1521
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEFERIPRONE

SMILES

Cc1c(c(=O)ccn1C)O

InChI

InChIKey=TZXKOCQBRNJULO-UHFFFAOYSA-N
InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://pubchem.ncbi.nlm.nih.gov/compound/deferiprone#section=Top; http://www.ncbi.nlm.nih.gov/pubmed/12825969

Deferiprone (trade name Ferriprox) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is an orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body. All the adverse effects of deferiprone are considered reversible, controllable and manageable. These include agranulocytosis with frequency of about 0.6%, neutropenia 6%, musculoskeletal and joint pains 15%, gastrointestinal complains 6% and zinc deficiency 1%.

Originator

Curator's Comment:: ApoPharma began formal development of deferiprone in 1993 (http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-adcom/documents/document/ucm275607.pdf; http://tircon.eu/tircon-partners/apopharma)

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
FERRIPROX

Approved Use

Indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival

Launch Date

1.31855037E12
Primary
FERRIPROX

Approved Use

Indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival. Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias.

Launch Date

1.31855037E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
64.8 μM
25 mg/kg single, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
118.8 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
150.8 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
60.8 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
35.2 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
51.4 ug/mL
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
54.4 ug/mL
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
34.1 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
30.6 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
33.4 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
43.3 ug/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
15001 μM × min
25 mg/kg single, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
205.5 ug*h/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
331.2 ug*h/mL
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
152.1 ug*h/mL
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
95.4 ug*h/mL
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
168 min
25 mg/kg single, oral
dose: 25 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.58 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
2.58 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
3.34999999999999 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum
Homo sapiens
2.5 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
2.6 h
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.8 h
50 mg/kg single, oral
dose: 50 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.8 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.77 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
2.03 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
2.2 h
33 mg/kg single, oral
dose: 33 mg/kg
route of administration: oral
experiment type: single
co-administered:
DEFERIPRONE serum
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
30 mg/kg 2 times / day multiple, oral
Recommended
Dose: 30 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg/kg, 2 times / day
Sources: Page: p.3
unhealthy, 29–71
n = 10
Health Status: unhealthy
Condition: Infratentorial superficial siderosis
Age Group: 29–71
Sex: M+F
Population Size: 10
Sources: Page: p.3
Disc. AE: Neutropenic sepsis, Fatigue...
AEs leading to
discontinuation/dose reduction:
Neutropenic sepsis (30%)
Fatigue (10%)
Sources: Page: p.3
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Disc. AE: Arthralgia, Joint effusion...
AEs leading to
discontinuation/dose reduction:
Arthralgia (non-serious)
Joint effusion (non-serious)
Nausea (non-serious)
Abdominal discomfort (non-serious)
Fatigue (non-serious)
Joint swelling (non-serious)
Epistaxis (non-serious)
Upper respiratory tract infections (non-serious)
Upper abdominal pain (non-serious)
Vomiting (non-serious)
Palpitation (non-serious)
Sources: Page: e475
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.3
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.3
Disc. AE: Aspartate aminotransferase increased, Alanine aminotransferase increased...
AEs leading to
discontinuation/dose reduction:
Aspartate aminotransferase increased (0.78%)
Alanine aminotransferase increased (0.16%)
Sources: Page: p.3
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.4
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.4
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (1.6%)
Vomiting (1.6%)
Abdominal pain (1.6%)
Sources: Page: p.4
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Sources: Page: p.1
Disc. AE: Agranulocytosis, Fetal damage...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis (grade 3-5)
Fetal damage
Sources: Page: p.1
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Other AEs: Neutropenia, Intestinal dilatation...
Other AEs:
Neutropenia (serious, 5 patients)
Intestinal dilatation (serious, 1 patient)
Intestinal obstruction (serious, 1 patient)
Volvulus (serious, 1 patient)
Obstruction (serious, 1 patient)
Pyrexia (serious, 1 patient)
Bacterial disease carrier (serious, 1 patient)
Bronchitis (serious, 2 patients)
Device related infection (serious, 1 patient)
Pneumonia (serious, 2 patients)
Wound infection (serious, 1 patient)
Chemical eye injury (serious, 1 patient)
Postoperative ileus (serious, 1 patient)
Toxicity to various agents (serious, 1 patient)
Unintentional medical device removal (serious, 1 patient)
Oromandibular dystonia (serious, 1 patient)
Device malfunction (serious, 1 patient)
Urinary bladder rupture (serious, 1 patient)
Choking (serious, 1 patient)
Cough (serious, 1 patient)
Respiratory disorder (serious, 1 patient)
Colectomy (serious, 1 patient)
Intestinal anastomosis (serious, 1 patient)
Intrathecal pump insertion (serious, 1 patient)
Laparotomy (serious, 1 patient)
Medical device battery replacement (serious, 2 patients)
Tracheostomy (serious, 1 patient)
Tracheostomy tube removal (serious, 1 patient)
Wound treatment (serious, 1 patient)
Thrombosis (serious, 1 patient)
Anaemia (below serious, 12 patients)
Influenza (below serious, 3 patients)
Pain (below serious, 4 patients)
Bronchitis (below serious, 7 patients)
Nasopharyngitis (below serious, 11 patient)
Rhinitis (below serious, 4 patients)
Upper respiratory tract infection (below serious, 8 patients)
Viral infection (below serious, 4 patients)
Laceration (below serious, 6 patients)
Body temperature increased (below serious, 3 patients)
Neutrophil count decreased (below serious, 10 patients)
Serum ferritin decreased (below serious, 19 patients)
Iron deficiency (below serious, 9 patients)
Arthralgia (below serious, 8 patients)
Muscle spasms (below serious, 3 patients)
Pain in extremity (below serious, 10 patients)
Dystonia (below serious, 25 patients)
Migraine (below serious, 3 patients)
Urinary incontinence (below serious, 3 patients)
Cough (below serious, 10 patients)
Oropharyngeal pain (below serious, 9 patients)
Rhinorrhoea (below serious, 4 patients)
Hyperhidrosis (below serious, 3 patients)
Rash (below serious, 4 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fatigue 10%
Disc. AE
30 mg/kg 2 times / day multiple, oral
Recommended
Dose: 30 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg/kg, 2 times / day
Sources: Page: p.3
unhealthy, 29–71
n = 10
Health Status: unhealthy
Condition: Infratentorial superficial siderosis
Age Group: 29–71
Sex: M+F
Population Size: 10
Sources: Page: p.3
Neutropenic sepsis 30%
Disc. AE
30 mg/kg 2 times / day multiple, oral
Recommended
Dose: 30 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg/kg, 2 times / day
Sources: Page: p.3
unhealthy, 29–71
n = 10
Health Status: unhealthy
Condition: Infratentorial superficial siderosis
Age Group: 29–71
Sex: M+F
Population Size: 10
Sources: Page: p.3
Abdominal discomfort non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Arthralgia non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Epistaxis non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Fatigue non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Joint effusion non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Joint swelling non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Nausea non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Palpitation non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Upper abdominal pain non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Upper respiratory tract infections non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Vomiting non-serious
Disc. AE
100 mg/kg multiple, oral (max|total daily dose)
Recommended
Dose: 100 mg/kg
Route: oral
Route: multiple
Dose: 100 mg/kg
Sources: Page: e475
unhealthy
n = 193
Health Status: unhealthy
Condition: Transfusion-dependent haemoglobinopathies
Sex: M+F
Population Size: 193
Sources: Page: e475
Alanine aminotransferase increased 0.16%
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.3
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.3
Aspartate aminotransferase increased 0.78%
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.3
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.3
Abdominal pain 1.6%
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.4
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.4
Nausea 1.6%
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.4
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.4
Vomiting 1.6%
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.4
unhealthy
n = 642
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Population Size: 642
Sources: Page: p.4
Fetal damage Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Sources: Page: p.1
Agranulocytosis grade 3-5
Disc. AE
33 mg/kg 3 times / day multiple, oral (max)
Recommended
Dose: 33 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 33 mg/kg, 3 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Transfusional iron overload due to thalassemia syndromes
Sources: Page: p.1
Cough below serious, 10 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Neutrophil count decreased below serious, 10 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Pain in extremity below serious, 10 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Nasopharyngitis below serious, 11 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Anaemia below serious, 12 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Serum ferritin decreased below serious, 19 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Dystonia below serious, 25 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Body temperature increased below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Hyperhidrosis below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Influenza below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Migraine below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Muscle spasms below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Urinary incontinence below serious, 3 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Pain below serious, 4 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Rash below serious, 4 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Rhinitis below serious, 4 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Rhinorrhoea below serious, 4 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Viral infection below serious, 4 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Laceration below serious, 6 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Bronchitis below serious, 7 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Arthralgia below serious, 8 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Upper respiratory tract infection below serious, 8 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Iron deficiency below serious, 9 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Oropharyngeal pain below serious, 9 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Bacterial disease carrier serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Chemical eye injury serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Choking serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Colectomy serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Cough serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Device malfunction serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Device related infection serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Intestinal anastomosis serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Intestinal dilatation serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Intestinal obstruction serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Intrathecal pump insertion serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Laparotomy serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Obstruction serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Oromandibular dystonia serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Postoperative ileus serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Pyrexia serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Respiratory disorder serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Thrombosis serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Toxicity to various agents serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Tracheostomy tube removal serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Tracheostomy serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Unintentional medical device removal serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Urinary bladder rupture serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Volvulus serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Wound infection serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Wound treatment serious, 1 patient
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Bronchitis serious, 2 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Medical device battery replacement serious, 2 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Pneumonia serious, 2 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Neutropenia serious, 5 patients
15 mg/kg 2 times / day steady, oral
Dose: 15 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 15 mg/kg, 2 times / day
Sources:
unhealthy
n = 58
Health Status: unhealthy
Condition: Pantothenate Kinase-associated Neurodegeneration
Population Size: 58
Sources:
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
no
no
no
no
no
no
no
no
yes
yes
yes
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Antimalarial effect of iron chelators.
2002
Long term deferiprone chelation therapy.
2002
Effects of deferiprone on immune status and cytokine pattern in thalassaemia major.
2002
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
2002 Aug 17
Deferiprone: greater efficacy at depleting myocardial than hepatic iron?
2002 Aug 17
Anti-leukemia activity of 7-hydroxy-2-substituted-methyl-5H-oxazolo[3,2-a]pyrimidin-5-one derivatives.
2002 Dec
Experience with the oral iron chelator deferiprone in transfusion-dependent children.
2002 Dec
Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria.
2002 Jan
Different complexation properties of some hydroxy keto heterocycles toward beryllium(II) in aqueous solutions: experimental and theoretical studies.
2002 Jul 29
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.
2002 Mar-Apr
Prodrug and covalent linker strategies for the solubilization of dual-action antioxidants/iron chelators.
2002 Nov 18
Iron toxicity and chelation therapy.
2002 Oct
Academic freedom in clinical research.
2002 Oct 24
Microbial growth-promotion activity of 3-hydroxymonoazine- and N-hydroxydiazine-type heterocycles.
2002 Sep
Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
2003
Iron deficiency and overload.
2003
Iron chelation in chemotherapy.
2003
Clinical research: a tale of two studies.
2003
Iron chelating agents for treating malaria.
2003
[Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].
2003
Antihistone and other autoantibodies in beta-thalassemia major patients receiving iron chelators.
2003
Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
2003 Apr
Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
2003 Apr
Do we need more iron-chelating drugs?
2003 Aug 9
Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
2003 Dec
Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives.
2003 Dec 15
Polyamine-iron chelator conjugate.
2003 Dec 4
The Olivieri case.
2003 Feb 27
The Olivieri Report--a compelling study of the growing tensions in clinical research.
2003 Jan
Patients' health or company profits? The commercialisation of academic research.
2003 Jan
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
2003 Jan 11
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
2003 Jan 11
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
2003 Jan 11
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
2003 Jan 11
Iron withdrawal strategies fail to prevent the growth of SiHa-induced tumors in mice.
2003 Jul
Role of deferiprone in chelation therapy for transfusional iron overload.
2003 Jul 1
Pulmonary dysfunction in transfusion-dependent patients with thalassemia major.
2003 Jul 15
Iron-dependent activation of NF-kappaB in Kupffer cells: a priming mechanism for alcoholic liver disease.
2003 Jun
Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
2003 Jun
Deferiprone and hepatic fibrosis.
2003 Jun 15
Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors.
2003 Jun 2
Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study.
2003 May
Glutathione depletion increases nitric oxide-induced oxidative stress in primary rat hepatocyte cultures: involvement of low-molecular-weight iron.
2003 May 15
Signaling role of intracellular iron in NF-kappaB activation.
2003 May 16
Pharmacotherapy of iron overload in thalassaemic patients.
2003 Oct
Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study.
2003 Sep
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
2003 Sep 1
Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs.
2004
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
2004 Jul
Superoxide, H2O2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase.
2004 Mar
Patents

Sample Use Guides

25 mg/kg to 33 mg/kg body weight, orally, three times per day, for a total daily dose of 75 mg/kg to 99 mg/kg body weight.
Route of Administration: Oral
Proliferating CD4+ T cells from control and RRMS subjects, cultured with or without IL-2, decreased in response to 75 μM deferiprone, although the extent of decreased proliferation of CD4+ T cells from RRMS subjects was less than for control subjects. Proliferating CD8+ T cells from control subjects, cultured with or without IL-2, also decreased in response to 75 μM deferiprone, and this decrease was seen in proliferating CD8+ T cells from RRMS cultured with IL-2.
Name Type Language
DEFERIPRONE
DASH   EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
4(1H)-PYRIDINONE, 3-HYDROXY-1,2-DIMETHYL-
Systematic Name English
DEFERIPRONE [EP MONOGRAPH]
Common Name English
NSC-758880
Code English
L-1
Code English
3-HYDROXY-1,2-DIMETHYLPYRIDIN-4(1H)-ONE
Systematic Name English
APO-66
Code English
DEFERIPRONE [MART.]
Common Name English
L1
Code English
DEFERIPRONE [ORANGE BOOK]
Common Name English
3-HYDROXY-1,2-DIMETHYL-4(1H)-PYRIDONE
Systematic Name English
DEFERIPRONE [INN]
Common Name English
DEFERIPRONE [EMA EPAR]
Common Name English
CP-20
Code English
DN-180-01-AF
Code English
DEFERIPRONE [VANDF]
Common Name English
DEFERIPRONE [WHO-DD]
Common Name English
DN-18001AF
Code English
CP20
Code English
DEFERIPRONE [USAN]
Common Name English
APO-066
Code English
DEFERIPRONE [MI]
Common Name English
DEFERIPRON
Common Name English
PL1
Code English
PL-1
Code English
Classification Tree Code System Code
EU-Orphan Drug EU/3/10/832
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
NCI_THESAURUS C62357
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
FDA ORPHAN DRUG 581217
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
EMA ASSESSMENT REPORTS FERRIPOX (AUTHORIZED: BETA-THALASSEMIA)
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
FDA ORPHAN DRUG 264308
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
LIVERTOX 273
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
FDA ORPHAN DRUG 340011
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
FDA ORPHAN DRUG 150701
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
NDF-RT N0000175522
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
WHO-ATC V03AC02
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
WHO-VATC QV03AC02
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
Code System Code Type Description
WIKIPEDIA
DEFERIPRONE
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
CAS
30652-11-0
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
ChEMBL
CHEMBL70927
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
INN
6958
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
MESH
C044919
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
DRUG BANK
DB08826
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
RXCUI
11645
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M4132
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY Merck Index
IUPHAR
7456
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
DRUG CENTRAL
4188
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
EPA CompTox
30652-11-0
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
EVMPD
SUB06941MIG
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
FDA UNII
2BTY8KH53L
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
LACTMED
Deferiprone
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
NCI_THESAURUS
C73030
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
HSDB
8335
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY
PUBCHEM
2972
Created by admin on Fri Jun 25 21:08:46 UTC 2021 , Edited by admin on Fri Jun 25 21:08:46 UTC 2021
PRIMARY